Trials / Completed
CompletedNCT00784940
ATAC - Bone Density Sub-Protocol
A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 308 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anastrozole | 1mg, orally, once daily |
| DRUG | Tamoxifen | 20mg, orally, once daily |
Timeline
- Start date
- 1998-06-01
- Primary completion
- 2005-03-01
- Completion
- 2007-04-01
- First posted
- 2008-11-04
- Last updated
- 2009-04-27
Source: ClinicalTrials.gov record NCT00784940. Inclusion in this directory is not an endorsement.